A retrospective to assess real world outcomes in patients with refractory/relapsed Hodgkin lymphoma treated with Brentuximab vedotine containing regimens
Latest Information Update: 08 Aug 2021
At a glance
- Drugs Brentuximab vedotin (Primary)
- Indications Hodgkin's disease
- Focus Therapeutic Use
- 08 Aug 2021 New trial record
- 17 Jun 2021 Results presented at the 26th Congress of the European Haematology Association